Nonhormonal Drug Eases Vasomotor Symptoms

BY MITCHEL L. ZOLER
Philadelphia Bureau

OTTAWA — A new, nonhormonal drug was safe and effective for reducing the incidence and severity of vasomotor symptoms of menopause in a series of three pivotal trials with a total of about 1,700 women.

If the drug, desvenlafaxine succinate, a serotonin-norepinephrine reuptake inhibitor (SNRI), is approved by the Food and Drug Administration, “it will be the first nonhormonal drug approved for treating hot flashes and nighttime awakenings,” Dr. Margery Gass said at the annual clinical meeting of the Society of Obstetricians and Gynaecologists of Canada. She and her colleague, Dr. Sophie Olivier, presented the data in five separate reports at the meeting.

“Women and their physicians are seeking an alternative to estrogen. What’s exciting is that this drug seems effective against hot flashes and mood, the things that trouble women during menopause,” commented meeting attendee Dr. Jennifer Blake, chief of ob.gyn at Sunnybrook Health Sciences Centre, Toronto.

Data from these studies were submitted by the drug’s developer, Wyeth, to the FDA in June 2006, and—as of late June of this year—action by the FDA for the indication of moderate to severe menopausal vasomotor symptoms was still pending. Last January, the FDA told Wyeth that desvenlafaxine was approvable for the indication of major depressive disorder, but final approval for that use is also still pending. As of late June, a Wyeth spokeswoman said that the company plans to market the drug with the trade name Pristiq for both indications.

The largest of the three pivotal trials enrolled 689 women who reported having 50 or more moderate or severe hot flash episodes a week. Patients were randomized to daily desvenlafaxine dosages of 50, 100, 150, or 200 mg, or placebo, and were scheduled to receive 52 weeks of treatment. The primary efficacy end point was the number and severity of hot flashes after 12 weeks of treatment, and the number of nighttime awakenings. Hot flash episodes and nighttime awakenings were recorded in daily diaries. Efficacy data were available for 620 of the enrolled women.

At baseline, these women had an average of about 11 hot flash episodes daily, with an average severity of 2.4 points (with measurements defined as severe [3 points], moderate [2 points], and mild [1 point]). They also reported an average of 3.7 awakenings a night.

Treatment with desvenlafaxine was most effective in this study at the 100-mg/day level. The 145 women on that dosage reported an average daily reduction of 1.76 hot flash episodes, compared with placebo, and an average drop in episode severity of 0.33 points, compared with the placebo effect. The frequency of nighttime awakenings fell by 0.56 episodes a night, compared with the placebo group. All of these changes were statistically significant compared with placebo, reported Dr. Gass, of the department of ob.gyn. at the University of Cincinnati. Dr. Gass disclosed that she receives compensation as a consultant to Wyeth. In Wyeth’s submissions to the FDA, it has proposed 100 mg/day as the recommended dosage, she said.

The placebo effect was substantial. The 77 women in the placebo group reported an average reduction of 6.3 hot flash episodes a day compared with their baseline number, an average drop in hot flash severity of 0.5 points, and an average drop in awakenings of 2.2 episodes a night.

Significantly more women were satis-

<table>
<thead>
<tr>
<th>Percentage of Patients Satisfied With Menopausal Vasomotor Symptom Relief</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>100 mg/day desvenlafaxine</strong></td>
</tr>
<tr>
<td><strong>(n = 145)</strong></td>
</tr>
<tr>
<td><strong>75%</strong></td>
</tr>
<tr>
<td><strong>52%</strong></td>
</tr>
</tbody>
</table>

Notes: Data based on 52 weeks of treatment. Differences between desvenlafaxine and placebo were statistically significant.
Source: Dr. Gass
fied with treatment when taking 100 mg desvenlafaxine daily, compared with those in the placebo group. (See box, p. 26) The researchers also evaluated the difference in treatment responses based on whether the women rated themselves as dissatisfied, neutral, or satisfied with their treatment response. The average incre

The ability of desvenlafaxine treatment to improve the POMS score is likely due to a direct antidepressant effect of the drug and to a secondary effect mediated by reduced vasomotor symptoms and improved sleep quality, Dr. Olivier said.

The third study involved 508 women who were randomized to daily treatment with 100 mg desvenlafaxine, 2.5 mg tiibolone, or placebo and were treated for 12 weeks. Tibolone (Xyvol), a synthetic hormone that is a selective estrogen-receptor modulator, is not approved for use in the United States but is approved for use in Europe and elsewhere. In this study, the 100 mg dosage of desvenlafaxine was not significantly different from placebo for reducing the frequency and severity of hot flashes and nighttime awakenings, and this dosage of desvenlafaxine was significantly worse than tibolone. In an analysis that combined the efficacy data collected in all three studies, the 100 mg/day and 150 mg/day dosages were each significantly better than placebo for reducing vasomotor symptoms. In addition, treatment with these dosages of desvenlafaxine produced the full treatment effect within 7 days of the start of treatment. In contrast, in the placebo group, the full effect of treatment was not seen until 4 weeks had elapsed.

The safety analysis involved a total of 1,131 patients treated with desvenlafaxine, including 495 treated for at least 12 weeks with the 100 mg/day dosage and 336 women treated with 150 mg/day. This analysis included 612 women assigned to treatment with desvenlafaxine for 52 weeks, including 155 women on 100 mg/day and 137 assigned to 150 mg/day. The results showed that desvenlafaxine was generally safe and well tolerated, with an adverse effect profile similar to those of other SNRIs.

The efficacy of the 100 mg dosage was confirmed in a second study that included 484 women who were randomized to either 100 mg or 150 mg desvenlafaxine daily or placebo, and were treated for 26 weeks. Again, the primary efficacy endpoints were measured after 12 weeks of treatment. The data from this second study were presented in a combined analysis with data from the first study, so that the total group included 843 women: 307 who received 100 mg/day desvenlafaxine, 281 who received 150 mg/day, and 255 who received placebo. The findings for number and severity of hot flashes and number of nighttime awakenings were similar to the results from the first study. The analysis also included a more detailed look at the effect of treatment on sleep. Women who received either the 100- or 150 mg dosage had significant increases in the number of minutes slept and in their self-reported sleep quality, compared with placebo patients, reported Dr. Sophie Olivier, senior director for clinical research and development at Wyeth.

This report included data on mood, based on the Profile of Mood States (POMS) questionnaire. The lower the POMS scores, the better a person’s mood, and a normal score is about 20 points or lower. At baseline, women in the combined study had an average score of 47. After 12 weeks of treatment, the POMS scores had dropped by an average of about 19 points in the women treated with desvenlafaxine, compared with an average fall of about 12 points among women in the placebo group, a significant difference.

CHD Risks With Diabetes or Metabolic Syndrome in Women: Role of TG and HDL-C

Of the estimated 16 million Americans with diabetes, more than half are women. In women, diabetes is a powerful risk factor for CHD, increasing CHD risk 3-fold to 7-fold compared to a 2-fold to 3-fold increase in men.4 It has also been shown that metabolic syndrome is associated with a 2-fold risk of CHD mortality in women.5 It is important to note that the most common pattern of dyslipidemia in patients with type 2 diabetes is elevated TG levels and decreased HDL-C levels.9,10

More Aggressive Guidelines for TG and HDL-C

While LDL-C lowering is recognized as the primary lipid target to reduce CHD morbidity and mortality, it does not remove all risk.9 Recent data has shed more light on the role of increased TG and decreased HDL-C in CHD risk. It is critical that these lipid abnormalities be considered and managed, in addition to LDL-C. In fact, the current National Cholesterol Education Program (NCEP) guidelines recommend more aggressive TG and HDL-C target goals.11 The American Heart Association (AHA) and American Diabetes Association (ADA) recommend similar aggressive goals for TG (<150 mg/dL) and HDL-C (>50 mg/dL) in CHD prevention for women.12

You Can Help Make a Difference

A majority of women are still not aware of the substantial CHD risks posed by abnormal lipid levels.12 As a physician, you can help make a difference by raising your female patients’ awareness of these issues, and by helping them achieve optimal lipid levels, as recommended by the NCEP, the AHA and the ADA.